Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Neoplasms 14Carcinoma, Hepatocellular 13Recurrence 12Brain Neoplasms 12Prostatic Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Glioblastoma 10Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Lymphocytic, Chronic, B-Cell 8Gliosarcoma 8Waldenstrom Macroglobulinemia 7Sarcoma 7Lung Neoplasms 7Glioma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Liver Neoplasms 5Kidney Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Follicular 4

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Thalidomide × Clear all
NCT00165230 2009-04-28

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡